News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Traversa Therapeutics, Inc. and Sanofi-Aventis K.K. Enter into a Research Agreement for the Development of Traversa's RNAi Delivery Technology



3/25/2010 10:30:31 AM

SAN DIEGO--(BUSINESS WIRE)--Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa’s RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES